Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

The Lead

Nanoparticles Target Cancer with Triple Threat

April 15, 2014 12:10 pm | News | Comments

Delivering chemotherapy drugs in nanoparticle form could help reduce side effects by targeting the drugs directly to the tumors, but it has been difficult to design particles that can carry any more than one or two drugs. Read more... 

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

2014 R&D 100 Awards Entry Deadline Extended

April 15, 2014 3:09 pm | News | Comments

The editors of R&D Magazine have announced that there is still plenty time to prepare your Entry Form for the 2014 R&D 100 Awards: Friday, May 2 is the new deadline.                      

New Product Launches Lift J&J in Q1

April 15, 2014 1:05 pm | by Linda Johnson, AP Business Writer | News | Comments

The world's biggest maker of health care products, such as Tylenol, medical devices and prescription drugs, easily beat Wall Street expectations and raised its earnings outlook, driving up its shares to a new high for the year. Read more...

TOPICS:

FDA Approves Merck’s Allergy Immunotherapy

April 15, 2014 12:59 pm | News | Comments

Merck announced that the FDA has approved Grastek (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use, an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis. Read more...   

TOPICS:
Advertisement

NICE Recommends Firmagon for Special Cases of Advanced Prostate Cancer

April 15, 2014 11:10 am | News | Comments

The National Institute for Health and Care Excellence issued its Final Appraisal Determination (FAD) recommending Firmagon (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. Read more...

TOPICS:

Regenerating Muscle in Duchenne Muscular Dystrophy

April 15, 2014 11:04 am | News | Comments

A team of scientists has published details of how a class of drugs called “HDACis” drive muscle-cell regeneration in the early stages of dystrophic muscles, but fail to work in late stages. Read more...              

TOPICS:

Potential New Way to Fight Malaria Drug Resistance

April 15, 2014 10:56 am | News | Comments

An anti-malarial treatment that lost its status as the leading weapon against the deadly disease could be given a new lease of life, with new research indicating it simply needs to be administered differently. Read more...        

TOPICS:

Mylan, Prosonix Enter Global Deal on Generic Respiratory Meds

April 15, 2014 10:44 am | News | Comments

Prosonix announced that it has entered into a global licensing agreement with Mylan Inc. for its leading inhaled respiratory products, PSX1001 and PSX1050, being developed as generic versions to GlaxoSmithKline’s pressurized metered dose inhalers. Read more...

TOPICS:

FDA OKs Trials for Vivolux First-in-Class Cancer Drug

April 15, 2014 10:32 am | News | Comments

Vivolux AB announced that the FDA has granted clearance to proceed with VLX600 into clinical Phase 1/2 trials. The drug candidate kills sleeping cell populations in regions of solid tumors that are metabolically compromised due to poor vascularization. Read more...

TOPICS:
Advertisement

Actavis Agrees to Generess FE Patent Settlement

April 15, 2014 10:22 am | News | Comments

Actavis plc announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess FE. Read more...             

TOPICS:

Ex Vivo Data Supports Mast's Sickle Cell Treatment

April 14, 2014 2:19 pm | News | Comments

Mast Therapeutics Inc. announced that, in an ex vivo study, MST-188 reduced the mean erythrocyte sedimentation rate (ESR) by 50% relative to control in blood collected from individuals with sickle cell disease. Read more...         

TOPICS:

Lexicon’s Type 1 Diabetes Trial Gets Positive Results

April 14, 2014 1:53 pm | News | Comments

Lexicon Pharmaceuticals Inc. announced positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which achieved the primary endpoint of reducing mealtime insulin use as well as several secondary endpoints, including improved glycemic control. Read more...

TOPICS:

J&J is First Collaborator in Scripps’ Drug Discovery Initiative

April 14, 2014 1:48 pm | News | Comments

The Scripps Research Institute (TSRI) announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates. Read more...

TOPICS:

FDA Accepts BI, Lilly NDA for Type 2 Diabetes Combo Tablet

April 14, 2014 1:39 pm | News | Comments

Boehringer Ingelheim and Eli Lilly and Co. announced that the FDA accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes. Read more...

TOPICS:

Mouse Model Breakthrough for Alzheimer's Research

April 14, 2014 1:27 pm | News | Comments

In a new study, a group of researchers has reported the creation of two new mouse models of Alzheimer’s disease that may potentially revolutionize research into this disease. Read more...                  

TOPICS:

BMS Files NDA for HIV Combo Treatment

April 14, 2014 12:59 pm | News | Comments

Bristol-Myers Squibb announced the submission of a new drug application (NDA) to the FDA for a fixed-dose combination of atazanavir sulfate and cobicistat that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading